drugset / Trial / NCT05047718
Factors Influencing the COVID-19 Vaccine Immune Response According to Age and Presence or Not of a Past History of COVID-19
Phase 4
Completed
54 enrolled
University Hospital of Saint-Etienne
Bioster, a.s. · collabSanofi Pasteur, a Sanofi Company · collab
Non-randomizedParallel-groupOpen-labelPrevention
Summary
Age is the main risk factor associated with the severity of COVID-19. From the beginning of the vaccination campaign, elderly subjects are part of the priority population. However, immunosenescence appears to play a role in the natural post-COVID-19 immunity of convalescent elderly subjects and also in the post-vaccination response. However, vaccination recommendations for both naïve (2 doses of vaccine) and convalescent subjects (1 dose of vaccine) do not differ according to age. To date, there is little data to suggest that the response to the vaccine in naïve or convalescent subjects may vary according to age in terms of qualitative and quantitative response and duration.
Timeline
- Start
- 2021-10-05
- Primary completion
- 2022-08-29
- Completion
- 2023-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | COVID-19 mRNA Vaccine Moderna | Vaccine | — | — |
| Subject | COVID-19 vaccine Pfizer | Vaccine | — | — |